Opinion|Videos|September 30, 2024

Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg

Fact checked by: Nikolas London, MD, FACS

Dr. London discusses the implications of faricimab and aflibercept 8 mg in treating retinal diseases, highlighting their mechanisms, efficacy data, and potential to enhance patient outcomes in conditions like wet age-related macular degeneration.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME